尿多酸肽治疗骨髓增生异常综合征的临床分析  

The Clinical Analysis of The Treatment of Uroacitides on Myelodysplastic Syndrome

作　　者：罗华山[1] 

机构地区：[1]梅州市人民医院血液内科,梅州514031

出　　处：《中国医药导刊》2012年第4期616-617,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:分析尿多酸肽治疗骨髓增生异常综合征的临床疗效与安全性。方法:统计并对比本院收治的骨髓增生异常综合征患者治疗前、后的粒细胞绝对计数(ANC)、血红蛋白(HB)、血小板(PLT)变化情况,同时统计不良反应发生率。结果:显效5例,显效率为45.45%;有效3例,有效率为27.27%;无效3例,无效率为27.27%,总有效率为72.73%。未见严重用药不良反应。经统计学检验,治疗后患者ANC、HB及PLT均明显优于治疗前,P<0.05。结论:尿多酸肽对于骨髓增生异常综合征的临床治疗具有疗效确切,安全可靠等优势,可于临床治疗中推广应用。Objective： To analyze the clinical efficacy and security of the treatment of uroacitides on myelodysplastic syndrome.Methods： Did statistics and comparison the change situation of absolute neutrophil counts（ANC）、hemoglobin（HB）、platelet（PLT） for patients with myelodysplastic syndrome admitted to our hospital before and after treatment,and at the same time did statistics on the incidence of adverse reactions.Results： 5 cases were markedly effective,the markedly effective rate was 45.45%;3 cases were effective,the effective rate was27.27%;3 cases were invalid,the invalid rate was27.27%,the total effective rate was72.73%.And there was no serious adverse reactions to medication.By the statistical test,ANC、HB and PLT of patients after treatment were significantly better than before treatment,（P0.05）.Conclusion： The clinical treatment of uroacitides on myelodysplastic syndrome is with the advantage of curative effect,safe and reliable Etc,can be promoted the application in the clinical treatment.

关 键 词：尿多酸肽 骨髓增生异常综合征 临床治疗 

分 类 号：R551.3[医药卫生—血液循环系统疾病]